Related Experiment Video

Updated: Jun 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Adenovirus-mediated cancer gene therapy and virotherapy (Review)

Takuya Fukazawa1, Junji Matsuoka, Tomoki Yamatsuji

  • 1Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. fukazawat@aol.com

International Journal of Molecular Medicine
|December 4, 2009
PubMed

Insights

Gene and virotherapies use targeted gene delivery to kill cancer cells. Novel promoter systems improve specificity, reducing toxicity to healthy tissues and advancing cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Gene therapy and virotherapy are emerging treatments for malignant tumors.
  • These therapies utilize therapeutic genes to induce cancer cell death.
  • Early gene therapy approaches faced challenges due to non-specific toxicity from ubiquitous promoters like CMV.

Purpose of the Study:

  • To review cancer- and/or tissue-specific gene therapy systems for cancer treatment.
  • To discuss advancements in targeting cancer cells while sparing normal tissues.
  • To explore challenges and future directions in cancer-targeting vector systems.

Main Methods:

  • Review of existing literature on gene therapy and virotherapy for cancer.
  • Discussion of promoter systems for targeted gene delivery.
  • Analysis of oncolytic virotherapy approaches.

Main Results:

  • Development of novel cancer- and/or tissue-specific promoter systems.
  • These systems aim to target cancer cells selectively, minimizing off-target effects.
  • Oncolytic virotherapy is presented as a key strategy.

Conclusions:

  • Cancer-specific and tissue-specific promoters enhance the safety and efficacy of gene therapy.
  • Targeted delivery systems are crucial for successful cancer treatment.
  • Further research is needed to overcome challenges in cancer-targeting vector systems.

More Related Videos

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...